Thymoma-associated myasthenia gravis (Q88649): Difference between revisions

← Older edit

@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank

Latest revision as of 14:58, 15 August 2026

In about 15% of the Acetylcholine receptor (AChR) positive Myasthenia Gravis patients, most common in 4th to 6th decades, the disease can be classified as paraneoplastic, usually associated with a thymoma. Thymoma with MG is equally or less malignant than that without MG. Anti-striational antibodies including anti-titin, ryanodine receptor (RyR), and Kv1.4 antibodies are more frequently found in thymoma-associated MG. In Muscle-specific kinase (MuSK) MG thymoma is rare, albeit small thymomas have been reported.

Language	Label	Description	Also known as
default for all languages	ID_704273188
English	Thymoma-associated myasthenia gravis	In about 15% of the Acetylcholine receptor (AChR) positive Myasthenia Gravis patients, most common in 4th to 6th decades, the disease can be classified as paraneoplastic, usually associated with a thymoma. Thymoma with MG is equally or less malignant than that without MG. Anti-striational antibodies including anti-titin, ryanodine receptor (RyR), and Kv1.4 antibodies are more frequently found in thymoma-associated MG. In Muscle-specific kinase (MuSK) MG thymoma is rare, albeit small thymomas have been reported.